

CURRICULUM VITAE

PERSONAL:

Name: Ali-Reza Golshayan, MD

Office Address: Medical University of South Carolina
96 Jonathan Lucas St, Suite 903, Charleston, SC 29425
Tel: (843) 792-4271
Fax: (843) 792-0644
Email: golshaya@musc.edu

EDUCATION:

1991 – 1995	Bachelor of Arts	Tufts University, Medford, MA
1996 – 2001	Medical Degree	University of Vermont College of Medicine, Burlington, VT

TRAINING:

7/2001 – 6/2002	Internship, Internal Medicine Cleveland Clinic Foundation, Cleveland, OH
7/2002 – 6/2004	Residency, Internal Medicine Cleveland Clinic Foundation, Cleveland, OH
7/2004 – 6/2007	Fellowship, Hematology & Medical Oncology: Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH
7/2007 – 6/2008	Fellowship, Experimental Therapeutics Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH

SPECIALITY / BOARD CERTIFICATION:

American Board of Internal Medicine (2004)
Medical Oncology (anticipated 2010)

LICENSURE:

South Carolina (7/2008 – present)

ACADEMIC APPOINTMENTS:

7/2008 – present Assistant Professor of Medicine
Medical University of South Carolina, Charleston SC

PROFESSIONAL ACTIVITIES:

Genitourinary Tumor Board (8/2008 – present)

Fellowship Research Committee (8/2008 – present)

MUSC Second Year Medical Student Physical Examination instructor (8/2008 – present)

Protocol Review Committee (1/09 – present)

Patient Flow Committee (2/10 – present)

Ad Hoc Manuscript Reviewer for peer-reviewed journals (Cancer, Journal of Urology, Clinical Genitourinary Cancer) (7/2008 – present)

2009 ASCO/AACR Workshop: Methods in Clinical Cancer Research (8/1-8/9/09)

PROFESSIONAL ORGANIZATIONS:

American Medical Association
American Society of Clinical Oncology
Southwest Oncology Group

AWARDS:

Freeman Medical Scholar (2000, 2001)

David M. Tormey Award “perseverance in the pursuit of a medical education” (2001)

PUBLICATIONS & BOOK CHAPTERS:

1. Rossillo A, Verma A, Saad EB, Corrado A, Gasparini G, Marrouche N, **Golshayan AR**, McCurdy R, Bhargava M, Khaykin Y, Burkhardt JD, Martin DO, Wilkoff BL, Saliba WI, Schweikert RA, Raviele A, Natale A. “Impact of Coronary Sinus Lead Position on Biventricular Pacing - Mortality and Echocardiographic Evaluation During Long-Term Follow-Up.” J Cardiovasc Electrophysiol 2004 Oct 15(10):1120-1125.

2. Sekeres MA, Fu AZ, Jaroslaw Maciejewski JP, **Golshayan AR**, Matt E. Kalaycio MW, Kattan MW. "A Decision analysis to determine the appropriate treatment for low-risk myelodysplastic syndromes." *Cancer*. 2007 Mar 15;109(6):1125-32
3. **Golshayan AR**, Jin T, Maciejewski J, Fu AZ, Bershinsky B, Kattan MW, Kalaycio ME, Sekeres MA. "Efficacy of Growth Factors compared to other therapies for Low-Risk Myelodysplastic Syndromes." *Br J Haematol*. 2007 Apr;137(2):125-32.
4. Choueiri TK, Garcia JA, Elson O, Khasawneh M, Usman S, **Golshayan AR**, Baz RC, Wood L, Rini BI, Bukowski RM. "Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy." *Cancer*. 2007 Jun 18;110(3):543-550
5. **Golshayan AR** and Bukowski RM. "Is temsirolimus more safe and effective than interferon α for the treatment of advanced renal cell carcinoma?" Practice Point Commentary. *Nat Clin Pract Urol*. 2007 4(11): 586-587.
6. **Golshayan AR**, Brick AJ, Choueiri TK. "Predicting outcome to VEGF-targeted therapy in metastatic clear-cell renal cell carcinoma: data from recent studies." *Future Oncol*. 2008 Feb;4(1):85-92
7. Choueiri TK, Vaziri SA, Jaeger E, Elson P, Wood L, Bhalla IP, Small EJ, Weinberg V, Sein N, Simko J, **Golshayan AR**, Sercia L, Zhou M, Waldman FM, Rini BI, Bukowski RM, Ganapathi R. "Von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear-cell renal cell carcinoma." *J Urol*. 2008 Sep;180(3):860-5.
8. J. Finke, B. Rini, J. Ireland, P. Rayman, A. Richmond, **A. Golshayan**, L. Wood, P. Elson, J. Garcia, R. Dreicer, R. Bukowski. "Sunitinib reverses type 1 immune suppression and decreases T regulatory cells in renal cell carcinoma patients." *Clin Cancer Res*. 2008 Oct 15;14 (20):6674-82.
9. **AR Golshayan**, RM Bukowski. "The role of sunitinib in metastatic renal cell carcinoma." *Hot Topics in Oncology*. 2008; Issue 4.
10. **Golshayan, AR**; George, S; Heng, D; Elson, P; Wood, L; Mekhail, T; Garcia, JA; Aydin, H; Zhou; Bukowski, R. "Metastatic Sarcomatoid Renal Cell Carcinoma Treated With VEGF-targeted Therapy." *Journal of Clinical Oncology*. 2009 Jan 10; 27:235-241.
11. J.S. Ko, A.H. Zea, B.I. Rini, J.L. Ireland, P. Elson, P. Cohen, **A. Golshayan**, P.A. Rayman, L. Wood, J. Garcia, R. Dreicer, R.M. Bukowski and J.H. Finke. "Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients." *Clin. Cancer Res.*, March 15, 2009; 15(6): 2148 - 2157.

12. DYC Heng, WL Xie, MM Regan, MA Warren, **AR Golshayan**, C Sahi, BJ Eigl, JD Reuther, T Cheng, S North, P Venner, JJ Knox, KN Chi, C Kollmannsberger, DF McDermott, WK Oh, MB Atkins, RM Bukowski, BI Rini, TK Choueiri. “Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor (VEGF)-targeted agents: Results from a large multicenter study.” *J Clin Oncol*. 2009 Dec 1;27(34):5794-9. Epub 2009 Oct 13.
13. Derek Raghavan, **Ali-Reza Golshayan**, Inderbir Gill, Cristina Magi-Galluzzi. “Tumors of the Renal Pelvis and Ureter.” *Holland-Frei Cancer Medicine* 8, Chapter 90, Published October 2009
14. Picard JC, **Golshayan AR**, Marshall DT, Opfermann KJ, Keane TE. “The multi-disciplinary management of high-risk prostate cancer.” *Urol Oncol*. 2009 Nov 26. [Epub ahead of print]
15. Khan G, **Golshayan A**, Elson P, Wood L, Garcia J, Bukowski R, Rini B. “Sunitinib and sorafenib in metastatic renal cell carcinoma patients with renal insufficiency.” *Ann Oncol*. 2010 Jan 20. [Epub ahead of print]
16. NS Basappa, P Elson, **A Golshayan**, L Wood, JA Garcia, R Dreicer, BI Rini. “The impact of tumor burden characteristics in metastatic renal cell carcinoma patients treated with sunitinib.” Submitted to *Cancer*, May 2010

ABSTRACTS & PRESENTATIONS:

1. Somerville J, **Golshayan A**. “Complex pulmonary atresia following radical repair. Long term costs of health care.” American College of Cardiology 10th International Symposium on Congenital Heart disease in the Adult. Toronto, Canada, July 1999. [Oral Presentation]
2. Sekeres MA, Jin T, Maciejewski J, Kalaycio ME, Brown S, Advani A, **Golshayan A**, Sobecks R, Kattan MW. “Characterization, resource use, and the economic impact of low-risk myelodysplastic syndrome (MDS) at an MDS specialty center.” *Journal of Clinical Oncology*. 2005 ASCO Annual Meeting Proceedings. Vol 23, No. 16S, Part I of II (June 1 Supplement), 2005: 6098 [Abstract]
3. Mikkael A. Sekeres, Alex Z. Fu, Jaroslaw P. Maciejewski, **Ali-Reza Golshayan**, Matt Kalaycio, Michael W. Kattan . “A Decision Analysis to Determine the Appropriate Treatment for Low-Risk Myelodysplastic Syndromes.” 2005 ASH Annual Meeting. *Blood*. 106: 11; November 16, 2005, Abstract #2533 [Poster Presentation]

4. **A. Golshayan**, A. Z. Fu, M. W. Kattan, S. Brown, J. P. Maciejewski, M. A. Sekeres “Efficacy of Growth Factors Compared to Chemotherapy in Low-Risk Myelodysplastic Syndromes.” 2005 ASH Annual Meeting. *Blood*. 106; 11: November 16, 2005, Abstract #2540. [Poster Presentation]
5. T.K. Choueiri, J.A. Garcia, B.I. Rini, S. Usman, M. Khasawneh, **A. Golshayan**, L. Wood, P. Elson and R.M. Bukowski. “Clinical Prognostic Factors in Metastatic RCC Patients Treated with Anti-VEGF therapy.” The Fifth International Kidney Cancer Symposium. September 23, 2006. [Oral Presentation]
6. **A. Golshayan**, T. K. Choueiri, P. Elson, J. A. Garcia, M. Khaswneh, S. Usman, I. Tamaskar, L. Wood, B.I. Rini, R.M. Bukowski. “Clinical factors associated with outcome in metastatic renal cell carcinoma patients treated with VEGF targeted therapy.” 2007 ASCO Annual Meeting. *Journal of Clinical Oncology* 25; 18S: (June 20 Supplement), 2007: 5046 [Poster Discussion]
7. K. Almhanna, **A. Golshayan**, M. Sands, A. Levitin, R. Kim, R. Pelley, S. Kalmadi. ”Response to trans-arterial chemoembolization prior to orthotopic liver transplantation or hepatic resection in patients with hepatocellular carcinoma.” *Journal of Clinical Oncology*, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 15114 [Abstract]
8. **A.R. Golshayan**, T.K. Choueiri, D. Heng, S. George, L. Wood, J.A. Garcia, B.I. Rini, R.M. Bukowski. “Survival update of risk group definitions associated with outcome in metastatic renal cell carcinoma (RCC) patients treated with VEGF-targeted therapy.” The Sixth International Kidney Cancer Symposium. October 13, 2007. [Oral Presentation]
9. **A.R. Golshayan**, S. George, D. Heng, T. Mekhail, T.K. Choueiri, P. Elson, L. Wood, J.A. Garcia, M. Zhou, B.I. Rini, R.M. Bukowski. “Metastatic renal cell carcinoma (RCC) with sarcomatoid differentiation treated with VEGF-targeted therapy.” The Sixth International Kidney Cancer Symposium. October 13, 2007. [Poster Presentation]
10. **A.R. Golshayan**, D.Y. Heng, S. George, T.K. Choueiri, P. Elson, L.S. Wood, T.M. Mekhail, J.A. Garcia, H. Aydin, M. Zhou, R.M. Bukowski, B.I. Rini. “Metastatic Sarcomatoid Renal Cell Carcinoma treated with VEGF-Targeted Therapy.” 2008 ASCO Genitourinary Cancers Symposium. February 16th 2008. [Oral Abstract Presentation]
11. **A.R. Golshayan**, S. George, P. Elson, L.S. Wood, J.A. Garcia, R.M. Bukowski, B.I. Rini. “VEGF-targeted therapy in metastatic renal cell carcinoma patients with renal insufficiency.” 2008 ASCO Genitourinary Cancer Symposium. February 16th 2008. [Poster Presentation]

12. S. George, J.A. Garcia, **A. Golshayan**, L. Wood, C. Nemece, T. Mekhail, P. Elson, R.M. Bukowski, B.I. Rini. "Dose escalation of sorafenib in metastatic renal cell carcinoma (mRCC) patients (pts)." 2008 ASCO Genitourinary Cancer Symposium. February 16th 2008. [Poster Presentation]
13. Lagwinski N., Choueiri T.K., **Golshayan A.**, Raghavan D., Hansel D.E. "Morphologic and Clinical Features in 41 Patients with Small Cell Carcinoma of the Bladder." USCAP 2008 Annual Meeting. March 1-7, 2008. [Poster Presentation]
14. **A.R. Golshayan**, S. George, D.Y. Heng, P. Elson, L. Wood, J.A. Garcia, H. Aydin, M. Zhou, R.M. Bukowski, B.I. Rini. "Metastatic renal cell carcinoma (mRCC) patients (pts) with sarcomatoid features treated with VEGF-targeted therapy." 2008 ASCO Annual Meeting. Journal of Clinical Oncology 26: 2008 (May 20 suppl; abstr 5102) [Poster Presentation]
15. H. Siddaiah, **A. R. Golshayan**, P. Elson, M. Zhou, J.A. Garcia, R.M. Bukowski, B.I. Rini. "Unclassified renal cell carcinoma (RCC): Analysis of clinical and pathologic features." 2008 ASCO Annual Meeting. Journal of Clinical Oncology 26: 2008 (May 20 suppl; abstr 16044) [Abstract]
16. S.A. Vaziri, **A.R. Golshayan**, B.I. Rini, H. Aydin, M. Zhou, L. Sercia, L. Wood, M.K. Ganapathi, R.M. Bukowski, R. Ganapathi. "The von Hippel Lindau (VHL) gene status is not always identical in paired primary (P) and metastatic (M) lesion in patients with clear cell renal cell carcinoma (CCRCC)." 2008 ASCO Annual Meeting. Journal of Clinical Oncology 26: 2008 (May 20 suppl; abstr 16049) [Abstract]
17. D.Y. Heng, P. Elson, **A.R. Golshayan**, M.A. Warren, C. Kollmannsberger, K.N. Chi, T. Cheng, S.A. North, J.A. Garcia, R.M. Bukowski, B.I. Rini. "A retrospective multicenter study of MSKCC poor-prognosis patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib." 2008 ASCO Annual Meeting. Journal of Clinical Oncology 26: 2008 (May 20 suppl; abstr 16057) [Abstract]
18. **A.R. Golshayan**, P. Elson, L. Wood, J.A. Garcia, R. Dreicer, B.I. Rini. "Impact of tumor volume on outcome in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib." 2009 ASCO Genitourinary Cancer Symposium. February 26th 2009. [Poster Presentation]
19. D.Y. Heng, W. Xie, M. Regan, M.A. Warren, T. Cheng, S.A. North, J.J. Knox, C. Kollmannsberger, D.F. McDermott, **A.R. Golshayan**, B.I. Rini, T.K. Choueiri. "Prognostic factors for overall survival (OS) in patients with metastatic renal cell carcinoma (RCC) treated with vascular endothelial growth factor (VEGF)-targeted agents: Results from a large multicenter study." 2009 ASCO Genitourinary Cancer Symposium. February 26th 2009. [Oral Presentation]

20. **A.R. Golshayan**, P. Elson, L. Wood, J.A. Garcia, R. Dreicer, B.I. Rini. "Tumor Burden Characteristics are Associated with Outcomes in Patients (pts) with Metastatic Renal Cell Carcinoma (mRCC) Treated with Sunitinib." 2009 ASCO Symposium. [Poster Discussion]
21. John A. Fortney, M.D., Andrew S. Kraft M.D., **Ali Golshayan M.D.**, Alan Brisendine CCRP, David T. Marshall, M.D. "Phase I Trial of Androgen Deprivation, Weekly Docetaxel and Concurrent Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of High-Risk Prostate Adenocarcinoma." Submitted to 2009 ASTRO meeting
22. U. B. Chaudhary, **A. R. Golshayan**, A. Brisendine, A. S. Kraft, J. A. Fortney, D. T. Marshall. "Phase I trial of androgen-deprivation therapy (ADT), weekly docetaxel (D), and intensity-modulated radiation therapy (IMRT) in patients (pts) with high-risk, clinically localized prostate cancer (PC)." 2010 ASCO Genitourinary Cancers Symposium, abstract#158. [Poster Presentation]
23. U. B. Chaudhary, **A. R. Golshayan**, A. Brisendine, A. S. Kraft, H. Clarke, T. E. Keane. "Phase II trial of neoadjuvant cisplatin, gemcitabine, and bevacizumab followed by radical cystectomy (RC) in patients with muscle-invasive transitional cell carcinoma (TCC) of the bladder." Submitted to 2010 ASCO Genitourinary Cancer Symposium.

INVITED PRESENTATIONS:

1. "Chemotherapy in the management of advanced urothelial carcinoma." MUSC Urology Grand Rounds. 3/10/2009
2. "Genitourinary Cancers." MUSC Oncology Nursing Rounds. 5/09/2009
3. "Culture and Family at the End of Life". MUSC Schwartz Center Rounds. Ali Golshayan, M.D., Cherlyn Monroe, MSW, and Hazel Huff, RN. 7/10/2009
4. "Targeted Therapy is the Best Treatment for Sarcomatoid RCC." Kidney Cancer Association's Eighth International Kidney Cancer Symposium. 09/25/2009.
5. "Treatment Options for Stage I Seminoma." MUSC Urology Grand Rounds. 9/29/09
6. "Prevention Strategies for Prostate Cancer." Cancer Prevention and Control Program Research Meeting, MUSC November 2009

CLINICAL PROTOCOLS AS PRIMARY INVESTIGATOR:

A Phase II Study of Neo-adjuvant Cisplatin, Gemcitabine, & Avastin, followed by Radical Cystectomy for Patients with Muscle invasive, Resectable, Non-Metastatic Transitional Cell carcinoma (TCC) of the Bladder

A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects with Castration Resistant Prostate Cancer that Have Received Prior Treatment with Docetaxel

Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer